Specifically, monoclonal antibodies targeting programmed cell death receptor‐1 (PD‐1) and programmed cell death ligand 1 (PD‐L1) have shown significant clinical benefits in malignancies such as lung cancer and melanoma [10]. This evidence concerns the gene CD274 and lung carcinoma.